HCV NS5B Polymerase Inhibitors

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 453-465

  Burton Jr , James R ^a   Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Clinical trials; Hepatitis C; Non nucleoside analog; Nucleoside analog; Polymerase inhibitors

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ABT 333; ANA 598; ANTIVIRUS AGENT; BILB 1941; ENZYME INHIBITOR; GS 9190; GSK 625433; IDX 184; MK 0608; NM 107; NM 203; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PF 868554; PLACEBO; PS 6130; R 1470; R 1728; R 7128; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; UNCLASSIFIED DRUG; VALOPICITABINE; VCH 759; VCH 916;

ANEMIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALAISE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; NUCLEOSIDES; PRODRUGS; PROTEASE INHIBITORS; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 67650631316     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.001     Document Type: Review

References (41)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36 5 Suppl 1 (2002) S3-20
2. Mann M.P., McHutchison J.G., Cordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
3. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
4. Torriani F.J., Rodriguez-Torres M., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
5. Chung T.R., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
6. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 2 (2006) 470-477
7. Mindikoglu A.L., and Miller R.R. Hepatitis C in the elderly; epidemiology, natural history and treatment. Clin Gastroenterol Hepatol 7 (2009) 128-134
8. Everson G.T. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 4 Suppl 1 (2004) S31-S38
9. Mann M.P., Foster G.R., Rockstroh J.K., et al. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 6 (2007) 991-1000
10. Kwong A.D., McNair L., Jacobson I., et al. Recent progress in the development of selected hepatitis C virus NS3-4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 8 (2008) 522-531
11. Zhou X.J., Afdhal N., Godofsky E., et al. Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: results from a phase I/II dose-escalation trial in patients with HCV-1 infection. [abstract]. J Hepatol 42 (2005) 229A
12. Godofsky E.W., Afdal N., Rustgi V., et al. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/III dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity on NM283, a novel antiviral treatment for hepatitis C. [abstract]. Gastroenterology 126 Suppl 2 (2004) A681
13. Afdhal N., O'Brian C., Godofsky E., et al. Valopicitabine (NM283), alone or with peginterferon, compared to peginterferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results. [abstract]. J Hepatol 46 (2007) S5
14. Valopicitabine development program placed on clinical hold in the United States [press release] (2007), Idenix Pharmaceuticals Inc, Cambridge (MA)
15. Roberts S.K., Cooksley G., Dore G.J., et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48 (2008) 398-406
16. Pockros P.J., Nelson D., Godofsky E., et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48 (2008) 285-297
17. Jiang W.-R., Chiu S., Ali S., et al. In vitro antiviral interactions of a novel HCV inhibitor R1479 with interferon α2a, ribavirin and other HCV inhibitors. [abstract]. Hepatology 44 Suppl 1 (2006) 533A
18. Nelson D., Pockros P., Godofsky E., et al. 84% end-of-treatment response (EOTR, week 48) achieved with R1626, peginterferon alfa 2a (40KD) and ribavirin for 4 weeks followed by the standard of care: Results of a phase 2a study in treatment-naïve HCV genotype 1 patients. [abstract]. J Hepatol 48 Suppl 2 (2008) S371
19. Pockros P., Nelson D., Godofsky E., et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 48 (2008) 1349-1350
20. Reddy R., Rodriguez-Torres M., Gane E., et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. [abstract]. Hepatology 46 Suppl 1 (2007) 862A
21. Rodriguez-Torres M., Lalezari J., Gane E., et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with Peg-IFN and ribavirin: subanalysis by race/ethnicity, eight and HCV genotype. [abstract]. Hepatology 48 Suppl (2008) 1160A
22. Gane E., Rodriguez-Torres M., Nelson D., et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders; results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days. [abstract]. Hepatology 48 Suppl 1 (2008) 1024A
23. Pharmasset and Roche obtain FDA consent to start a phase 2b study with R7128 in treatment naive HCV patients [press release] (2009), Pharmasset Inc., Princeton (NJ)
24. Cretton-Scott E., Perigaud C., Peyrottes S., et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. [abstract]. J Hepatol 48 Suppl 2 (2008) S220
25. Accessed from Idenix website, Available at:. www.indenix.com Accessed February 14, 2009
26. Carrol S.S., Ludmerer S., Handt L., et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53 (2009) 926-934
27. Kneteman N.M., How A.Y.M., Goa T., et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C. Hepatology 49 (2009) 745-752
28. Chandra P., Moyer L., Harper D., et al. Safety and pharmacokinetics of the non-nucleoside polymerase inhibitor, HCV-796: results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects. J Hepatol 44 Suppl 2 (2006) S208-S209
29. Villano S.A., Raible D., Harper D., et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naïve patients with chronic HCV. [abstract]. J Hepatol 46 (2007) S24
30. Villano S., Howe A., Raible D., et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor in treatment naïve HCV-infected patients. [abstract]. Hepatology 44 Suppl 1 (2006) 607A
31. Press release. ViroPharma announces discontinuation of HCV-796 development (2008), ViroPharma, Exton (PA)
32. Pockros PJ, Rodriguez-Torres M, Villano S, et al. A phase 2, randomized study of HCV-796 in combination with PEG-Intron plus Rebetol (RBV) versus PEG-Intron plus RBV in hepatitis C virus genotype 1 infection. European Association for the Study of Liver Disease Annual Meeting. Copenhagen, Denmark. April 22-29, 2009.
33. Erhardt A., Wedemeyer H., Benhamou Y., et al. Safety, pharmacokinetics and antiviral effects of BILB 1941, a novel HCV RNA polymerase, after 5 days oral treatment in patients with chronic hepatitis C. [abstract]. J Hepatol 44 Suppl (2007) S222
34. Hammond J.L., Rosario M.C., Wagner F., et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. [abstract]. Hepatology 48 Suppl 1 (2008) 267A
35. Vliegen I., Paeshuyse J., Marbery E., et al. GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. [abstract]. Hepatology 46 Suppl 1 (2007) 855A
36. Bavisotto L., Wang C.C., Jacobson I.M., et al. Antiviral, pharmacokinetic and safety data for GS 9190, a non-nucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. [abstract]. Hepatology 46 Suppl 1 (2007) 255A
37. Cooper C., Lawitz E.J., Ghali P., et al. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized double blind placebo controlled ascending multiple dose study. [abstract]. Hepatology 46 Suppl 1 (2007) 864A
38. Proulx L., Bourgault B., Chauret N., et al. Results of safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers. J Hepatol 48; Suppl 2 (2008) S320-S321
39. ANA598 (Anadys Pharmaceuticals). Available at:. www.anadyspharma.com Accessed February 14, 2009
40. Lalezari J., Gane E., Rodriguez-Torres M., et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days. [abstract]. J Hepatol 48 Suppl 2 (2008) S29
41. Sulkowski M.S. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep 9 (2007) 5-13